NASDAQ:MLND - Millendo Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $3.80
  • Forecasted Upside: 291.63 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$0.97
▼ -0.0197 (-1.99%)
1 month | 3 months | 12 months
Get New Millendo Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MLND and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MLND

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$3.80
▲ +291.63% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Millendo Therapeutics in the last 3 months. The average price target is $3.80, with a high forecast of $6.00 and a low forecast of $2.00. The average price target represents a 291.63% upside from the last price of $0.97.
Hold
The current consensus among 6 investment analysts is to hold stock in Millendo Therapeutics. This rating has held steady since August 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
10/27/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
1/25/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
4/24/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
7/23/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/21/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
1/19/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
3/20/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
4/19/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/6/2021SVB LeerinkDowngradeOutperform ➝ Market Perform$5.00 ➝ $2.00N/A
i
Rating by J. Schwartz at SVB Leerink LLC
1/6/2021LADENBURG THALM/SH SHDowngradeBuy ➝ NeutralN/A
i
8/12/2020WedbushReiterated RatingHold$3.00Low
i
Rating by L. Chico at Wedbush
6/14/2020SVB LeerinkReiterated RatingOutperform$5.00Medium
i
6/14/2020Roth CapitalReiterated RatingBuy$6.00Medium
i
Rating by Y. Rahimi at Roth Capital
5/29/2020CitigroupInitiated CoverageBuy$6.00High
i
Rating by Joel Beatty at Citigroup Inc.
5/21/2020OppenheimerReiterated RatingHold$2.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
4/19/2020OppenheimerDowngradeOutperform ➝ Market PerformMedium
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
4/7/2020Roth CapitalLower Price Target$35.00 ➝ $6.00Medium
i
Rating by Y. Rahimi at Roth Capital
4/6/2020OppenheimerDowngradeOutperform ➝ Market Perform$25.00 ➝ $2.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
4/6/2020WedbushDowngradeOutperform ➝ Neutral$25.00 ➝ $4.00High
i
Rating by L. Chico at Wedbush
3/24/2020CitigroupLower Price TargetBuy$23.00 ➝ $20.00Low
i
Rating by Joel Beatty at Citigroup Inc.
2/7/2020CitigroupInitiated CoverageBuy$23.00High
i
1/20/2020SVB LeerinkReiterated RatingOutperformMedium
i
Rating by J. Schwartz at SVB Leerink LLC
1/10/2020Roth CapitalInitiated CoverageBuy$35.00High
i
Rating by Y. Rahimi at Roth Capital
9/16/2019Jefferies Financial GroupReiterated RatingBuy$22.00High
i
8/15/2019WedbushReiterated RatingBuy$24.00Low
i
Rating by L. Chico at Wedbush
8/13/2019OppenheimerLower Price TargetOutperform$26.00 ➝ $25.00Low
i
7/18/2019WedbushInitiated CoverageOutperform$24.00Low
i
Rating by L. Chico at Wedbush
7/16/2019CIBCInitiated CoverageOutperform ➝ Outperform$26.00Medium
i
7/16/2019OppenheimerInitiated CoverageOutperform$26.00 ➝ $26.00High
i
7/15/2019CitigroupInitiated CoverageOutperform$26.00High
i
3/13/2019Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$22.00High
i
1/4/2019LADENBURG THALM/SH SHInitiated CoverageBuy ➝ Buy$29.00N/A
i
12/13/2018SVB LeerinkInitiated CoverageOutperform ➝ Outperform$24.00N/A
i
Rating by J. Schwartz at SVB Leerink LLC
(Data available from 4/19/2016 forward)
Millendo Therapeutics logo
Millendo Therapeutics, Inc. operates as a biopharmaceutical company. The company is headquartered in Ann Arbor, Michigan.
Read More

Today's Range

Now: $0.97
$0.96
$1.02

50 Day Range

MA: $1.79
$1.04
$2.33

52 Week Range

Now: $0.97
$0.96
$3.64

Volume

330,019 shs

Average Volume

908,839 shs

Market Capitalization

$18.48 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.12

Frequently Asked Questions

What sell-side analysts currently cover shares of Millendo Therapeutics?

The following sell-side analysts have issued reports on Millendo Therapeutics in the last year: Citigroup Inc., LADENBURG THALM/SH SH, Oppenheimer Holdings Inc., Roth Capital, SVB Leerink LLC, Wedbush, and Zacks Investment Research.
View the latest analyst ratings for MLND.

What is the current price target for Millendo Therapeutics?

5 Wall Street analysts have set twelve-month price targets for Millendo Therapeutics in the last year. Their average twelve-month price target is $3.80, suggesting a possible upside of 283.8%. Roth Capital has the highest price target set, predicting MLND will reach $6.00 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $2.00 for Millendo Therapeutics in the next year.
View the latest price targets for MLND.

What is the current consensus analyst rating for Millendo Therapeutics?

Millendo Therapeutics currently has 4 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in MLND, but not buy more shares or sell existing shares.
View the latest ratings for MLND.

What other companies compete with Millendo Therapeutics?

How do I contact Millendo Therapeutics' investor relations team?

Millendo Therapeutics' physical mailing address is 110 MILLER AVENUE SUITE 100, ANN ARBOR MI, 48104. The company's listed phone number is 734-845-9000 and its investor relations email address is [email protected] The official website for Millendo Therapeutics is www.millendo.com.